Trial Profile
A Multinational, Multicenter, Observational, Exposure Registry Study to Compare the Birth Defects in Teriflunomide Treated Pregnant Women with Those Reported by European Surveillance of Congenital Anomalies (EUROCAT)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Jul 2018
Price :
$35
*
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 19 Jun 2018 Results (n=14, data cut off Apr 2017) presented at the 4th Congress of the European Academy of Neurology
- 21 Aug 2015 New trial record
- 20 Jun 2015 Trial design presented at 1st Congress of the European Academy of Neurology